LARIAM
LOE ApproachingNDAORALTABLET
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARIAM (mefloquine) is an oral antimalarial small molecule approved by Roche in 1989 for malaria prevention and treatment. The drug is indicated for travelers and at-risk populations in endemic regions. Its mechanism of action involves disruption of the Plasmodium parasite's nucleic acid synthesis.
LOE Approaching
Late-stage product with moderate competitive pressure (30%) signals defending market share rather than expansion; smaller commercial teams focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LARIAM offers stable but non-growth career opportunities in a mature, well-defined product category. Roles emphasize defensive positioning, cost management, and compliance rather than market expansion or innovation.
Brand ManagerMedical Science Liaison
Worked on LARIAM at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.